Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Core Insights - Aethlon Medical has achieved a significant milestone by treating the first patient with the Hemopurifier in a clinical trial targeting solid tumors that do not respond to anti-PD-1 therapies [1][3] - The trial aims to assess the safety, feasibility, and dosing of the Hemopurifier in patients with stable or progressive disease after anti-PD-1 monotherapy [5] Company Overview - Aethlon Medical, Inc. is a publicly traded medical device company based in San Diego, California, focused on developing therapeutic devices to treat cancer and life-threatening infectious diseases [7] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation, potentially improving responses to existing cancer therapies [6][7] Clinical Trial Details - The clinical trial involves approximately 18 patients and will monitor the incidence of adverse events and changes in safety lab tests after treatment with the Hemopurifier [5] - The study will also evaluate the number of Hemopurifier treatments required to decrease extracellular vesicle concentrations and whether this enhances the body's ability to attack tumor cells [5] Treatment Context - Only 30-40% of patients receiving pembrolizumab or nivolumab show lasting clinical responses, highlighting the need for alternative treatment strategies [4] - The Hemopurifier has shown promise in preclinical studies by reducing the number of exosomes in cancer patient plasma, which may help overcome resistance to anti-PD-1 therapies [4][6]